Emerging anti-obesity agents (e.g., GLP- 1 receptor agonists, triple incretin agonists) show superior efficacy, necessitating formulation optimization for BBR to achieve clinical competitiveness. The gene discussed is GLP1R; the disease is obesity disorder.